OBESITY · White paper
Obesity Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About obesity — and why its trials are hard
Obesity is a chronic, relapsing disease of excess adiposity (BMI >=30 kg/m2) shaped by genetic, hormonal, behavioral and environmental factors. U.S. adult prevalence has climbed from roughly 30% in 2013 to over 42% by 2023, and the WHO estimates more than 650 million adults are affected worldwide. Once viewed as a lifestyle failing, obesity is now understood through neuroendocrine appetite pathways (leptin, ghrelin, GLP-1/GIP), driving a wave of highly effective incretin-based pharmacotherapies. The regulatory bar for FDA approval is a mean placebo-adjusted weight loss with a categorical responder threshold (at least 5% body weight in a proportion double that of placebo). The field has moved from modest agents (orlistat, phentermine-topiramate, naltrexone-bupropion) to GLP-1 receptor agonists (liraglutide ~5-8%, semaglutide ~15%) and the dual GIP/GLP-1 agonist tirzepatide (~21%). Trials must contend with strong placebo/lifestyle responses, high dropout from gastrointestinal side effects, weight regain after discontinuation, and demand for long-term cardiometabolic and safety follow-up.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | 2021 | Chronic weight management in adults with obesity or overweight plus a comorbidity (with diet and exercise) | STEP 1 (NCT03548987) | Mean % change in body weight and proportion achieving >=5% loss at 68 weeks | -14.9% with semaglutide vs -2.4% placebo (difference ~12.4%); 83.5% achieved >=5% loss vs 31.1% |
| Tirzepatide (Zepbound) | 2023 | Chronic weight management in adults with obesity or overweight plus a comorbidity (dual GIP/GLP-1 agonist) | SURMOUNT-1 (NCT04184622) | Mean % change in body weight at 72 weeks | Up to ~20.9-22.5% mean weight loss at the highest dose vs ~2-3% placebo |
| Liraglutide 3.0 mg (Saxenda) | 2014 | Chronic weight management in adults with obesity or overweight plus a comorbidity (GLP-1 agonist, daily injection) | SCALE Obesity and Prediabetes (NCT01272219; program NCT01842382) | Mean % change in body weight and >=5%/>=10% responders at 56 weeks | -7.4% vs -3.0% placebo (difference ~4.5%); 62.3% achieved >=5% loss vs 34.4% |
| Phentermine-topiramate ER (Qsymia) | 2012 | Chronic weight management in adults with obesity or overweight plus comorbidities | CONQUER (NCT00553787) / EQUIP program | Mean % weight loss and >=5%/>=10% responders at 56 weeks | At 15/92 mg, ~67-70% achieved >=5% loss vs ~17-21% placebo; ~9% mean reduction |
| Naltrexone-bupropion ER (Contrave) | 2014 | Chronic weight management in adults with obesity or overweight plus comorbidities | COR-I (NCT00532779; program NCT01193084) | Mean % change in body weight and >=5% responders at 56 weeks | -5.4% vs -1.3% placebo (difference ~4.1%); 42% achieved >=5% loss vs 17% |
| Orlistat (Xenical) | 1999 | Weight loss/maintenance in obesity, including patients with comorbidities (lipase inhibitor) | XENDOS (4-year study) | Mean % weight loss and diabetes incidence | -5.2% vs -2.8% placebo at 4 years; cumulative diabetes incidence 5.5% vs 8.3% |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in obesity development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rimonabant (CB1 antagonist) — RIO program (e.g., NCT00263042) | Never approved in the U.S.; withdrawn in Europe | Severe psychiatric adverse effects (depression, anxiety, suicidality) yielding an unfavorable risk-benefit for a CNS-acting agent |
| Lorcaserin — CAMELLIA-TIMI 61 (post-marketing safety) | Approved 2012 but voluntarily withdrawn from the market in 2020 | Post-marketing data showed an increased incidence of cancer, underscoring long-term safety surveillance needs |
| Beloranib (MetAP2 inhibitor) — NCT02063295 (Prader-Willi program) | Development terminated after FDA clinical hold | Two patient deaths from thromboembolic (venous) events raised fatal cardiovascular safety concerns |
Choosing the right endpoint
Primary endpoints that matter in obesity trials
- Percentage of body weight loss — Primary efficacy endpoint; FDA expects a clinically meaningful mean difference plus a categorical >=5% responder rate roughly double placebo
- Categorical responder analysis (>=5%, >=10%, >=15%) — Proportion of patients crossing weight-loss thresholds; higher thresholds distinguish next-generation incretin agents
- Maintenance of weight loss — Sustained loss for at least one year addresses the chronic, relapsing nature of obesity and weight regain on discontinuation
- Cardiometabolic markers — HbA1c, blood pressure, lipids and waist circumference capture benefits beyond weight; MACE outcomes (e.g., SELECT) support cardiovascular claims
- Quality of life / PROs — Validated instruments such as IWQOL-Lite standardize physical and psychosocial functioning outcomes
How iNGENū runs obesity trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Obesity clinical trials — FAQs
What is the primary endpoint the FDA expects in obesity trials?
How much weight loss do the newer GLP-1 based drugs achieve?
Why do obesity drug candidates fail?
Ready to discuss your obesity trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal